Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...

Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene therapy trials, allowing the company to resume testing its experimental drug ...

Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...

Intellia (NTLA) stock jumps as the FDA lifts clinical hold on MAGNITUDE-2 Phase 3 trial for its nex-z gene editing drug ...

Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene ...

The company said Tuesday that the FDA lifted the hold on an Investigational New Drug Application for a phase 3 clinical trial of nexiguran ziclumeran, or nex-z, for patients with a genetic disease ...

Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock soared 20% Tuesday after the U.S. Food and Drug Administration (FDA) lifted a clinical hold on the company’s MAGNITUDE-2 Phase 3 trial for ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

The FDA has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 phase 3 trial of nexiguran ziclumeran, or nex-z: a CRISPR-based gene therapy for patients with hereditary transthyretin ...

Gene editing company Intellia Therapeutics has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the ...

Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.